A methylpyrrole-carboxylate from RYANIA that disrupts the RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL to modify CALCIUM release from SARCOPLASMIC RETICULUM resulting in alteration of MUSCLE CONTRACTION. It was previously used in INSECTICIDES. It is used experimentally in conjunction with THAPSIGARGIN and other inhibitors of CALCIUM ATPASE uptake of calcium into SARCOPLASMIC RETICULUM.
Ryanodine has been studied across 17 research domains including 🦴 Bone & Joint, 🏋️ Muscle & Hypertrophy, 🔥 Metabolic, ❤️ Cardiovascular, 🧠 Focus & Attention. The primary research focus is 🦴 Bone & Joint with 96% of studies addressing this area.
The following compounds share molecular targets with Ryanodine, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Ryanodine is generated deterministically from 299 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.